相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
Monia Marchetti et al.
Lancet Haematology (2022)
Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study
Walter Ageno et al.
BLOOD ADVANCES (2022)
Splanchnic vein thrombosis associated with myeloproliferative neoplasms
Douglas Tremblay et al.
THROMBOSIS RESEARCH (2022)
European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera
Douglas Tremblay et al.
HEMASPHERE (2022)
Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis
Marta Magaz et al.
JOURNAL OF HEPATOLOGY (2021)
Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis
Emanuele Valeriani et al.
BLOOD (2021)
Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis
Jean-Jacques Kiladjian et al.
JOURNAL OF HEPATOLOGY (2021)
Overview of Myeloproliferative Neoplasms History, Pathogenesis, Diagnostic Criteria, and Complications
Douglas Tremblay et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2021)
Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases
Patrick G. Northup et al.
HEPATOLOGY (2021)
Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia
Douglas Tremblay et al.
FRONTIERS IN ONCOLOGY (2021)
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
Tiziano Barbui et al.
LEUKEMIA (2021)
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
Emanuela Sant'Antonio et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience
Douglas Tremblay et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis
Alberto Alvarez-Larran et al.
ANNALS OF HEMATOLOGY (2020)
Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation
Leonard Naymagon et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)
Venous thrombosis of the liver: current and emerging concepts in management
Leonard Naymagon
TRANSLATIONAL RESEARCH (2020)
Anticoagulant therapy for splanchnic vein thrombosis ISTH SSC Subcommittee Control of Anticoagulation
Marcello Di Nisio et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses
Pierre-Edouard Debureaux et al.
BLOOD ADVANCES (2020)
Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
Alexandre Guy et al.
HEMASPHERE (2020)
The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis
Leonard Naymagon et al.
BLOOD ADVANCES (2020)
Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression
Alexandre Guy et al.
HAEMATOLOGICA (2019)
Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population
Sabrina Cordua et al.
BLOOD (2019)
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
J. Mascarenhas et al.
LEUKEMIA (2019)
Splanchnic Vein Thrombosis: Current Perspectives
Emanuele Valeriani et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2019)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location
Dawid T. Janczak et al.
MAYO CLINIC PROCEEDINGS (2018)
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
Ofir Wolach et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
Guido Finazzi et al.
BLOOD CANCER JOURNAL (2018)
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
Valerio De Stefano et al.
BLOOD CANCER JOURNAL (2018)
Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study
Johanne Poisson et al.
JOURNAL OF HEPATOLOGY (2017)
NCCN Guidelines® Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines
Ruben A. Mesa et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
J. I. Weitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease
Joan How et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2017)
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms
Lisa Pieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Contemporary management of acute and chronic deep venous thrombosis
Prakash Saha et al.
BRITISH MEDICAL BULLETIN (2016)
Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series
Yan Beauverd et al.
HAEMATOLOGICA (2016)
Guidance for the management of venous thrombosis in unusual sites
Walter Ageno et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2016)
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
V. De Stefano et al.
LEUKEMIA (2016)
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
V. De Stefano et al.
BLOOD CANCER JOURNAL (2016)
Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series
Yan Beauverd et al.
HAEMATOLOGICA (2016)
Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms
Andrej Potthoff et al.
LIVER INTERNATIONAL (2015)
Myeloproliferative Neoplasms A Contemporary Review
Ayalew Tefferi et al.
JAMA ONCOLOGY (2015)
Selected parameters of hemostasis in patients with myeloproliferative neoplasms
Grazyna Gadomska et al.
BLOOD COAGULATION & FIBRINOLYSIS (2014)
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera
Federico Lussana et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients
T. Rusak et al.
FREE RADICAL RESEARCH (2014)
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation
Vittorio Rosti et al.
BLOOD (2013)
CANCER-ASSOCIATED THROMBOTIC DISEASE Myeloproliferative neoplasms and thrombosis
Tiziano Barbui et al.
BLOOD (2013)
Splanchnic vein thrombosis in myeloproliferative neoplasms
Mallika Sekhar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Good Long-Term Outcome of Budd-Chiari Syndrome With a Step-wise Management
Susana Seijo et al.
HEPATOLOGY (2013)
Apixaban for Extended Treatment of Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
Alberto Alvarez-Larran et al.
BLOOD (2012)
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis
Jasper H. Smalberg et al.
BLOOD (2012)
Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia
Alberto Alvarez-Larran et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia
Juan-Carlos Hernandez-Boluda et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms
J. Hoekstra et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Thrombosis in primary myelofibrosis: incidence and risk factors
Tiziano Barbui et al.
BLOOD (2010)
Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders
Brady L. Stein et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Splanchnic vein thrombosis: clinical presentation, risk factors and treatment
Valerio De Stefano et al.
INTERNAL AND EMERGENCY MEDICINE (2010)
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis
Francesco Dentali et al.
BLOOD (2009)
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome
Selcuk Sozer et al.
BLOOD (2009)
Portal Hypertension-Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation
Juan Turnes et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
Valerio De Stefano et al.
HAEMATOLOGICA (2008)
Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin α5 chain and Lu/BCAM
Marie-Paule Wautier et al.
BLOOD (2007)
Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications
Naseema Gangat et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: The role of neutrophils
A Falanga et al.
SEMINARS IN HEMATOLOGY (2005)
Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders
MK Jensen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
